Skip to main content
SpringerLink
Log in

Outlook for transplant recipients with CMV infection improved with appropriately targeted treatment

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hebart H, Kanz L, Jahn G, et al. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation: current guidelines and future prospects. Drugs 1998 Jan; 55(1): 59–72

    Article  PubMed  CAS  Google Scholar 

  2. Meyers JD, Flourney N, Thomas E. Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis 1986; 153: 478–88

    Article  PubMed  CAS  Google Scholar 

  3. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term aciclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation: European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–53

    Article  PubMed  CAS  Google Scholar 

  4. Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12: 273–82

    PubMed  CAS  Google Scholar 

  5. Boeckh M, Gooley T, Reusser P, et al. Failure of high-dose acyclovir for prevention of CMV disease after autologous marrow transplant. J Infect Dis 1995; 172: 939–43

    Article  PubMed  CAS  Google Scholar 

  6. Patel R, Wiesner RH, Paya CV. Prophylaxis and treatment of cytomegalovirus infection after solid organ transplantation. Clin Immunother 1996 Jan; 5(1): 13–29

    Article  Google Scholar 

  7. Stratta RJ, Wood RP, Langnas RM, et al. Donor selection for orthotopic liver transplantation: lack of an effect of gender or cytomegalovirus (CMV) status. Transplant Proc 1990; 22: 410–3

    PubMed  CAS  Google Scholar 

  8. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279–89

    Article  PubMed  CAS  Google Scholar 

  9. Balfour Jr HH, Chace BA, Stapleton JT, et al. A randomised, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381–7

    Article  PubMed  Google Scholar 

  10. Winston DJ, Wirin D, Shaked A, et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 69–74

    Article  PubMed  CAS  Google Scholar 

  11. Kelly JL, Albert RK, Wood DE, et al. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995; 59: 1144–7

    PubMed  CAS  Google Scholar 

  12. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients — a meta-analysis. Clin Transplant 1994; 8: 10–8

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Outlook for transplant recipients with CMV infection improved with appropriately targeted treatment. Drugs Ther. Perspect 12, 10–13 (1998). https://doi.org/10.2165/00042310-199812110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199812110-00004

Search

Navigation